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a b s t r a c t
Objective: The occurrence of psychiatric comorbidity among individuals with crack or
inhalant dependence is frequently observed. The objective of this study was to investigate
anxiety symptoms among crack cocaine and inhalant users in southern Brazil.
Methods: The study investigated two groups of volunteers of equal size (n=50): one group
consisted of crack cocaine users, and the other group consisted of inhalant users. Research
volunteers completed the Portuguese versions of the State-Trait Anxiety Inventory (STAI),
Hamilton Anxiety Rating Scale (HAM-A), and Self-Report Questionnaire (SRQ).
Results: Both crack and inhalant users experience signiﬁcant symptoms of anxiety. Inhalant
users presented signiﬁcantly more anxiety symptoms than crack users according to the
HAM-A questionnaire only. In contrast to the results of the HAM-A, the STAI failed to
demonstrate a signiﬁcant difference between the two groups of substance users. SRQ scores
revealed that crack and inhalants users had signiﬁcant degrees of morbidity.
Conclusion: A signiﬁcant difference regarding anxiety symptomatology, especially state
anxiety, was observed among inhalant and crack users. Anxiety and overall mental
psychopathology were signiﬁcantly correlated in this sample. The results indicate that
screening initiatives to detect anxiety and additional psychiatric comorbidities among crack
and inhalant users are feasible and relevant.
© 2013 Elsevier Editora Ltda.
Sintomas de ansiedade em usuários de crack e inalantes admitidos
em uma unidade psiquiátrica na Região Sul do Brasil
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Objetivo: Investigar sintomas de ansiedade em usuários de crack e inalantes no Sul do Brasil.
Métodos: Oestudo investigoudois gruposdevoluntários comomesmonúmerode indivíduos
(n=50): um grupo consistiu de usuários de crack e o outro grupo, de usuários de inalantes.
 Study conducted at Universidade de Caxias do Sul and Clínica Paulo Guedes, Caxias do Sul, RS, Brazil.
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Ansiedade
Brasil
Questionários
Os voluntários da pesquisa completaram as versões em português das escalas de ansiedade
State-Trais Anxiety Inventory (STAI) e Hamilton Anxiety Rating Scale (HAM-A), e o Questionário
de Autoavaliac¸ão (SRQ).
Resultados: Ambos os grupos apresentaram sintomas signiﬁcativos de ansiedade. Os
usuários de inalantes apresentaram escores quanto a HAM-A signiﬁcativamente superiores
aos usuários de crack. Ansiedade e psicopatologia geral se apresentaram signiﬁcativamente
correlacionados.
Conclusão: Sintomas de ansiedade são frequentes entre usuários de crack e inalantes. Um
processo de triagem de sintomas de ansiedade entre usuários de crack e inalantes deve
facilitar ainda mais as intervenc¸ões terapêuticas nesta área.
© 2013
Introduction
Crack and inhalant abuse have been documented as two of the
most common addictive disorders in Brazil.1,2 Crack cocaine
and inhalants have been used in Brazil by street children,3
undergraduates,4 and medical students.5,6 Inhalants abuse
and dependence negatively affect youth regardless of gender,
ethnicity, age, and family income.7 The association between
inhalant dependence and other psychiatric morbidities is
higher than in patients with dependence to other psychoac-
tive drugs, including alcohol.8
The co-occurrence of mood and anxiety disorders has been
predominantly associated with adverse outcomes among
young substance users.9 The prevalence ﬁgures of anxiety
disorders among substance users vary according to differ-
ent studies.10 In the Drug Abuse Treatment Outcome Study
(DATOS), which assessed over 10,000 substance users, the
prevalence of generalized anxiety disorder (GAD) ranged from
2.2% to 4.2%,11 while in studies with smaller sample sizes the
prevalence rates of anxiety disorders varied substantially.12–14
Symptoms of anxiety were also the most common psychiatric
manifestation among adolescents with substance use-related
disorders (60% of both boys and girls).15 The signiﬁcant asso-
ciation between any anxiety disorder and lifetime cocaine use
has been consistently detected in an independent survey con-
ducted in the US and Canada.16 In a Spanish cross-sectional
study, nearly 42.5% of cocaine users recruited in non-clinical
settings presented with a psychiatric comorbidity; anxiety
disorders (13%) were the second most common comorbid
disorder, after depression.17 Data from an international mul-
ticenter study revealed that the onset of anxiety disorders
usually precedes the initiation of substance use disorders.18
The use of cocaine may precipitate panic attacks, phobia
reactions, obsessions, and compulsions, which may persist
after discontinuation of use.19,20 The comorbidity between
cocaine use and social phobia21 and post-traumatic stress
disorder (PTSD)22,23 tends to occur among individuals with
severe cocaine use, with personal background and family
history of psychiatric disorders.24 The association between
anxiety disorder and cocaine use has been described in the
context of affective disorder,25,26 and documented extensively
among people with panic attacks.27–29 Treatment-seeking
cocaine users also report signiﬁcant levels of anxiety.14 Anx-
iety and mood disorders were the most common comorbid
Axis I disorders diagnosed in a sample of male inpatients in
Iowa.30 Anxiety is also a prominent clinical feature during the
abstinencephase of cocainewithdrawal.31 In comparisonwith
users of heroin only, users of both heroin and cocaine present
signiﬁcantly more symptoms of anxiety.32 Anxiety has also
been considered as a risk factor for the occurrence of cocaine-
induced paranoia.33
Anxiety disorders are commonly associated with inhalant
use. The reported prevalence rate of generalized anxiety dis-
order among inhalant users is 20.5%.8 Data from a national
epidemiological survey revealed that inhalant users had a
signiﬁcant lifetime prevalence of anxiety disorders (36%).34
Female inhalant users presented higher lifetime prevalence
rates of any anxiety disorder in comparison with male users
(53% versus 30%), including panic disorder without agora-
phobia (25% versus 11%), and speciﬁc phobia (28% versus
14%). Female inhalant users also were more likely to have
met the criteria for three or more anxiety disorders (15%
versus 8%) in the past year.34 In addition, adolescents with
inhalant abuse or dependence are signiﬁcantly more likely to
have abuse or dependence of alcohol, hallucinogens, nicotine,
cocaine, and/or amphetamines, and are more likely to have
attempted suicide compared with other adolescent patients
who reported never using inhalants.35 Toluene is the main
component of inhalants used by youth in Brazil, including
homeless youth, as conﬁrmed by urinary levels of hippuric
acid.36,37
Considering the frequent occurrence of psychiatric comor-
bidity among individuals with crack or inhalant dependence,
as well as the compounding and detrimental effects of this
association, it is essential to carefully screen these drug
users for anxiety.35,38 Furthermore, the majority of individuals
affected by anxiety disorders have never obtained effective
treatment despite the signiﬁcant level of disability imposed by
these conditions.39 The objective of this study was to inves-
tigate anxiety symptoms among crack cocaine and inhalant
users in southern Brazil. To the authors’ knowledge, this is
the ﬁrst time that crack and inhalant users have been simul-
taneously assessed with two anxiety-speciﬁc measures in
southern Brazil.
Methods
Sample
The study investigated two groups of volunteers of equal size
(n=50): one group consisted of crack cocaine users and the
other group consisted of inhalant users. Both groups were
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interviewed as inpatient volunteers in wards of a tertiary care
mental health facility and a higher education training site
associated with the Universidade de Caxias do Sul. Drug users
fulﬁlled the Diagnostic and Statistic Manual of Mental Disor-
ders, 4th edition (DSM-IV) diagnostic criteria for crack cocaine
or inhalant dependence, according to a psychiatric interview
conducted upon admission by psychiatrists who were com-
pletely unfamiliar with this research protocol. Patients with
polydrug dependence had to satisfy the inclusion criteria of
using either crack cocaine or any type of inhalant drug as (a)
themain addictive substance, and (b) the one causing themost
salient dependence.
All patients who volunteered to participate in this inves-
tigation were assisted via the Brazilian public health system.
Taking into account that a substantial fraction of the sam-
ple was illiterate or semi-illiterate, all drug users completed
the questionnaires under minimal guidance by trained inter-
viewers, who followed standardized instructional procedures.
Uncompleted or inappropriately completed questionnaires
were excluded from analysis. All volunteers spoke Portuguese
as their ﬁrst language.
Informed consent and recruitment
This study was endorsed by the institutional Ethics and
Research Committees of the Universidade de Caxias do
Sul (UCS), which regulate all scientiﬁc activities at UCS.
All volunteers signed a informed consent. A certiﬁcate of
conﬁdentiality was guaranteed to all research participants.
Consent from parents or legally responsible adults was
obtained before minor participants were formally enrolled in
the present study. All respondents were treated anonymously.
Research participantswere recruited viaword-of-mouth. Drug
userswere approached to participate in this study after having
achieved a stable clinical course, as determined by their own
physician. The recruitment process took place during various
consecutive months, according to the rate of hospital admis-
sions of prospective participants. Research participants were
interviewed only once for the purpose of this investigation.
Research tools
The State-Trait Anxiety Inventory (STAI) is one of the most
widely used self-report measures of anxiety in clinical and
research settings.40 The STAI measures two different compo-
nents: state anxiety,which refers to a transitory and subjective
emotional state that varies over time; and trait anxiety, which
refers to a relatively stable pattern of reaction to stress with
anxiety anda tendency toperceive situations as threatening.41
The Portuguese version of the STAI was validated in a sample
of university students in Brazil.42 Each part varies from 20 to
80 points, and the scores indicate low (0–30), medium (31–49),
or high (50 or more) anxiety levels.41
TheHamiltonAnxiety Rating Scale (HAM-A)was conceived
as an easy-to-use instrument to measure state anxiety.43 The
HAM-A has been used extensively to investigate symptoms of
anxiety as well as the result of interventions aimed at reduc-
ing levels of anxiety.44 The Portuguese version of the HAM-A
has been widely used for measuring mainly state anxiety.45
A score of 17 or below indicates absence of or low levels of
anxiety; a score from 18 to 24 indicates low to moderate anx-
iety levels; while a score from 25 to 30 indicates moderate to
severe anxiety levels.46
The Self-Reporting Questionnaire (SRQ) was used to iden-
tify minor and general psychiatric morbidity.47 The SRQ was
derived from research instruments used by the World Health
Organization (WHO) for studying psychiatric morbidity in pri-
mary care settings in developing countries.48,49 According to
SRQ, respondents were classiﬁed as high (≥ 8) or low (≤ 7)
scorers.50
The socio-economic status (SES) of research participants
was assessed via a scale previously tested in Brazil.51 This
instrument classiﬁes SES into six categories: lower-lower,
upper-lower, lower-middle, upper-middle, lower-upper, and
upper-upper class.
Statistical analyses
Analysis of demographic variables was performed in rela-
tion to age and socioeconomic status. The overall scores of
the HAM-A, STAI, and SRQ were computed and subsequently
transformed into Z-scores for correlation and regression anal-
yses. Student’s t-test for independent samples was performed
to examine differences between two groups of drug users.
Analyses of correlation via Pearson’s product-moment and
Spearman’s rank coefﬁcients were computed between the
questionnaires’ scores and categories, respectively. Logistic
regression analyses were also conducted to explore predictive
effects of anxiety scales (HAM-A and STAI) on general psy-
chopathology (SRQ). Statistical analyseswere conducted using
the Statistical Package for Social Sciences (SPSS®).
Results
Demographic data
The mean age in the overall sample was 20.2 years of age. The
mean ages in the groups of crack users and inhalant users
were 22.8 and 17.3 years of age, respectively. Regarding gen-
der, the overall sample had 12% and 88% of female and male
volunteers, respectively. Table 1 showsa summaryof all demo-
graphic information.
Regarding SES, most of the total sample was classiﬁed
as upper-lower class (30%) and lower-middle class (59%). A
nonparametric analysis via Kruskal-Wallis test of the two
subgroups differentiated according to SES strata revealed an
absence of a signiﬁcant difference in themedians between the
two groups, with 2 (1, n= 100) = 2.15, p= 0.142.
Anxiety
The mean scores of the both anxiety rating scales used in
this study (HAM-A and STAI), in the combined sample of
crack and inhalant users and in each separate group are
shown in Table 2. According to the HAM-A classiﬁcation,
71.7% of the sample did not have or had low levels of anx-
iety, while 28.3% presented anxiety. Considering each group
separately, crack users and inhalants users presented the fol-
lowing results, respectively: 90% and 53.1% (absence or low
rev assoc med bras . 2013;59(4):360–367 363
Table 1 – Sociodemographic characteristics of the total sample of substance users
Sociodemographic characteristics Total (n=100) Crack (n=50) Inhalant (n=50)
Age
Mean (± SD) 20.1 (6.2) 22.8 (6.4) 17.3 (4.5)
Range 29 (11-40) 17 (11-28) 25 (15-40)
Gender
Male 88 43 (86%) 45 (90%)
Female 12 7 (14%) 5 (10%)
Socio-economic status
Lower-lower 3 1 (2%) 2 (4%)
Upper-lower 32 15 (30%) 17 (34%)
Lower-middle 57 28 (56%) 29 (58%)
Middle 8 6 (12%) 2 (4%)
levels of anxiety), and 10% and 46.9% (presence of anxiety).
Among crack users who experienced anxiety, 4% presented
light to moderate levels of anxiety, while 6% presented mod-
erate to severe levels of anxiety. Among inhalant users who
experienced anxiety, 28.6% reported light to moderate levels
of anxiety, while 18.4% presented moderate to severe levels of
anxiety.
The STAI classiﬁed crack and inhalant users, in terms of
presence or absence of anxiety, taken together, as follows: 9%
(absence or low levels of anxiety) and 91% (presence of anx-
iety). The distribution according to the presence or absence
of anxiety as classiﬁed by the STAI in the groups of crack
and inhalant users, respectively, was as follows: 14% and 4%
(absence or low levels of anxiety), and 86% and 96% (pres-
ence of anxiety). Among crack users who experienced anxiety,
72% presented medium levels of anxiety, while 14% presented
high levels of anxiety. Among inhalant users who experienced
anxiety, 78% reported medium levels of anxiety, while 18%
presented high levels of anxiety.
A parametrical analysis using Student’s t-test for inde-
pendent samples revealed a signiﬁcant statistical difference
between the two groups of drug users according to the scores
of the HAM-A anxiety ratings scale: t (97) =−4.62, p<0.001.
A nonparametric analysis using the Mann-Whitney test of
HAM-A scores according to a categorical distinction (absence
or presence of anxiety, based on a cut-off point of > 17, as
explained in the Methods section) also revealed a signiﬁcant
difference among the groups of crack and inhalant users, with
z=−4.06, p<0.001. This signiﬁcant difference persisted when
the three different categories of intensity were taken into
account (z=−3.9, p < 0.001).
A parametrical analysis using Student’s t-test for indepen-
dent samples revealed an absence of signiﬁcant statistical
difference between the two groups of drug users according to
the STAI scores: t (98) = -1.54, p = 0.13. A nonparametric analy-
sis using the Mann-Whitney test of STAI scores according to a
categorical distinction (absence or presence of anxiety, based
on a cut-off point of ≥ 31, as explained in the Methods section)
also revealed an absence of signiﬁcant difference between the
groups of crack and inhalant users, with z=−1.74, p=0.8. The
absence of signiﬁcant difference persisted when the different
categories of intensity were analyzed (z=−1.37, p=0.17).
Correlation analyses
Pearson product-moment correlation coefﬁcients were com-
puted among the overall scores of all questionnaires
completed by the three groups. The Bonferroni method was
used to control for type I error for all pair wise comparisons:
PC = 0.05/3 = 0.17.
A signiﬁcant correlation was found between the scores of
the HAM-A and the scores of the STAI in the combined sample
of drug users (r = 0.43, p< 0.001). Spearman’s rank correlation
analysis also revealed a signiﬁcant association between the
caseness (presence or absence of anxiety) generated by the
HAM-A and the STAI (=2; p<0.05).
Signiﬁcant correlationswere also foundbetween the scores
of HAM-A and SRQ (r = 0.44, p< 0.001) and between the scores
of STAI and SRQ (r = 0.67, p< 0.001).
Linear regression analyses
Bivariate linear regression analyses were conducted, sepa-
rately, to evaluate the prediction of general psychopathology
scores (SRQ) according to the scores of the anxiety rating scales
among crack and inhalant users.
Table 2 – Scores and case details of crack and inhalants users according to the HAM-A and the STAI questionnaires
HAM-A STAI
Mean (SD) Absence/low levels
of anxiety (%)
Presence of
anxiety (%)
Mean (SD) Absence/low levels
of anxiety (%)
Presence of
anxiety (%)
Crack (n=50) 8.38 (8.07) 90 10 48.06 (10.52) 14 86
Inhalant (n=50) 16.45 (9.28) 53.1 46.9 51 (8.39) 4 96
Both groups 12.37 (9.54) 71.7 28.3 49.53 (9.58) 9 91
HAM-A, Hamilton Anxiety Rating Scale; STAI, State-Trait Anxiety Inventory.
364 rev assoc med bras . 2013;59(4):360–367
3
2
1
0
–1
–2
–3 –2 –1 0 1 2 3
SR
Q
STAI
R Sq Linear = 0.447
3
2
1
0
–1
–2
–2 –1 0 1 2 3
HAM-A
R Sq Linear = 0.244
SR
Q
Fig. 1 – Scatter plots demonstrating the linear correlation
between the SRQ (general psychopathology) and the STAI
and HAM-A (anxiety) questionnaires.
SRQ, Self-Report Questionnaire; STAI, State-Trait Anxiety
Inventory; HAM-A; Hamilton Anxiety Rating Scale.
An initial analysis to predict changes in the SRQ scores,
having the HAM-A scores as a predictor, revealed that the
two variables were linearly related, such that as the overall
anxiety symptomatology increases, the magnitude of gen-
eral psychopathology also increases. The linear predictive
ability was signiﬁcant (95% CI: 0.32-0.67). Approximately 24%
of the variance of the SRQ scores was accounted for by its
linear relationship with the HAM-A. A similar linear regres-
sion analysis was conducted to evaluate the prediction of
the SRQ scores using the STAI scores as a predictor. The
results indicated that the SRQ scores and the STAI scores
are also linearly related. The correlation was signiﬁcant (95%
CI: 0.52-0.82). Approximately 45% of the variance of the SRQ
score was accounted for by its linear relationship with the
STAI.
The scatter plots of the two bivariate linear regression anal-
yses mentioned above are presented in Fig. 1.
Discussion
The results presented in this study indicate that both crack
and inhalant users experience signiﬁcant symptoms of anxi-
ety. The prevalence of anxiety among crack users varies from
10% (HAM-A) to 86% (STAI), while among inhalant users the
ﬁgures vary from 46.9% (HAM-A) to 96% (STAI). Crack users
presented signiﬁcantlymore anxiety symptoms than inhalant
users according to the HAM-A questionnaire only. This differ-
ence was observed when results were treated parametrically
and non-parametrically. These ﬁndings are consistent with
results obtained by other studies, which revealed that anxiety
is, among other psychiatric symptoms, a frequent comor-
bidity among crack cocaine users.17 Crack cocaine users, in
particular, are known to present with signiﬁcant psychiatric
comorbidities, including depression, anxiety disorders, bipo-
lar disorder, and attention-deﬁcit/hyperactivity disorder, with
eventual fatal outcomes.52,53 In Brazil, treatment-seekingnon-
intravenous cocaine users presented a lifetime prevalence
of Axis I or Axis II disorders of 69%, and anxiety disor-
ders were the most common psychiatric disorder (31%).54
The higher prevalence of anxiety disorders among cocaine
dependent subjects encompasses different dysfunctions such
as general anxiety, phobic, panic, and obsessive-compulsive
disorders.55 Although the physiological and psychoactive
effects of cocaine are similar regardless of its hydrochloride
or crack form, evidence indicates a greater abuse liability and
propensity for dependence, as well as more severe conse-
quences, when cocaine is smoked or injected intravenously
in comparison with intranasal use.56 In Brazil, a signiﬁcant
tendency to change routes of administration and patterns of
cocaine use has been documented by several studies in the
last decade.1,44,57–60
Contrarily to the results of the HAM-A, the STAI failed
to demonstrate a signiﬁcant difference between the two
groups of substance users. There are conceptual differences
between the two scales used to evaluate anxiety in this
sample. The HAM-A measures state anxiety, which is a symp-
tomatic expression, while the STAI also captures trait anxiety,
which is related to characteriological issues.45 The differences
between “state” and “trait” anxiety reﬂect the conceptual dis-
tinction between existing anxiety as a transitory state and the
anxiety as a relatively stable personality characteristic.61,62
STAI scores may suffer from being inﬂuenced by different
illness variables, such as severity, chronicity, and comorbid-
ity of symptoms.63 Although variations in ratings have been
reported with the HAM-A as well,64,65 the STAI was unable to
distinguish between anxiety and depression in a mixed group
of patients with both conditions, from which the authors con-
cluded that the STAI does have clinical utility for measuring
emotional distress.63 In the present study, only the trait subset
of the STAI was used. The results of this study suggest there-
fore that trait anxiety is not signiﬁcantly affected by crack and
inhalant use, and that only measures of state anxiety should
be used for the assessment of anxiety related to cocaine and
inhalant use.
Considering the contrasting results produced by differ-
ent scales used to measure anxiety, there is an increased
need to investigate possible differences in the symptomatic
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measurement among patients with anxiety.63 Although psy-
chometric measures have been produced extensively in
psychiatry, sometimes via a single assessment tool, it has
been advocated that anxiety and depression may be similar
elements of a general psychological distress experience of dif-
ﬁcult differentiation.66 Likewise, depression is a disorder with
important clinical signiﬁcance among crack cocaine users. A
previous study detected a lifetime prevalence of 17.8% for
depressionamong crack cocaineusers.67 Prevalence of depres-
sion among crack users is believed to be higher than what has
been previously reported.68 Furthermore, studies that investi-
gated depressive disorders among crack users have detected
additional psychiatric comorbidities, including anxiety, bipo-
lar disorder, and attention-deﬁcit/hyperactivity disorder, with
eventual fatal outcomes.52,53
Regarding psychiatric morbidity, the scores generated by
the SRQ revealed that crack and inhalants users had signiﬁ-
cant degrees of morbidity. The SRQ has been previously used
as general screening tool for mental disorders in the context
of substance abuse.69–72 Furthermore, in a community-based
study conducted in southern Brazil, in which 126 adoles-
cents were screened for mental problems, the prevalence
of depressive symptoms, suicidal ideation, and hopelessness
were higher among those who were detected as SRQ-positive
according to a cut-off score of ≥ 8,73 the same threshold used
in the present study.
The results of Pearson correlation analyses also revealed a
signiﬁcant correlation among anxiety symptoms and general
psychopathology, which attest to a congruent measurement
of the constructs investigated in this study. Furthermore,
the results of the bivariate linear regression analyses also
revealed that the scores of the two anxiety rating scales
used in this study can predict, with signiﬁcant accuracy,
the scores of general psychopathology of crack and inhalant
users.
Previous evidence, based on regression analyses of data
from a national survey in the United States, revealed that
inhalant users had greater odds of intravenous drug use
than users who had not used inhalants.34 The results pre-
sented here reveal a direct and predictive association between
depressive symptoms and general mental disorder among
crack and inhalant users. Although additional studies are
required to further substantiate these ﬁndings, these results
may recommend more rigorous and extensive screening
efforts to detect and treat depressive symptoms among crack
and inhalant users.
This studymaypresent some limitations, especially in rela-
tion to the nature of the sample investigated. Some of these
discrepancies were revealed in the analyses of demographic
data. Firstly, regarding age range, inhalant users presented
a lower mean age in comparison with crack users. The rea-
sons for the early age of inhalant use are based on the
fact that many organic solvents are present in wide array
of chemical compounds publicly commercialized for a broad
variety of household purposes, which facilitate children’s
access. In fact, inhalant use has been characterized as pref-
erentially prevalent among children and juveniles in both
developed and developing economies.74–79 In Brazil, as well
as in other developing countries, inhalants tend to be the
preferred drug used among the street children, who are who
live and wander unsupervised on the streets of major urban
centers.80
Secondly, male participants predominated signiﬁcantly in
both groups. Evidence based on a series of surveys conducted
with Brazilian secondary school students demonstrated an
increased use of illicit psychotropic drugs by males, while
women prefer to use drugs in the form of pills, such as anxi-
olytics and amphetamines.81
Thirdly, the psychometric tools used in this study were not
speciﬁcally designed to evaluate adolescents. Although the
mean age in the overall sample was 20.1 years, the mean age
of inhalant users was 17.3 years. Nevertheless, most of the
instruments used in this study have been tested previously
as screening tools among adolescents in southern Brazil.73
Furthermore, the unavailability of versions validated in Por-
tuguese of instruments developed speciﬁcally for assessing
adolescents’ mental health prevented, at this stage, the use
of a more suitable methodology for this sample. This limita-
tion highlights the need for validation studies of psychometric
instruments among adolescents in Brazil.
Despite the above-mentioned limitations, the sample
investigated in this study was recruited in public health facil-
ities, where members of all socio-economic strata of the
Brazilian society have prompt access to health care. This
advantage is particularly relevant in the case of a study con-
ducted in a developing economy, where inequalities of care
are known to produce signiﬁcant health differentials.82
Conclusion
A signiﬁcant difference regarding anxiety symptomatology,
especially state anxiety, was observed among inhalant and
crackusers. Anxiety andoverallmental psychopathologywere
signiﬁcantly correlated in this sample. The results indicate
that screening initiatives to detect anxiety and additional psy-
chiatric comorbidities among crack and inhalant users are
feasible and relevant. Considering that drug abuse, especially
of inhalants, affect youth preferentially, and that adolescence
is a vulnerable life cycle phase, the present ﬁndings justify
more rigorous and extensive screening efforts to detect and
treat anxiety disorders among crack cocaine and inhalant
users.
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